

11-1-01

The PTO did not receive the following listed items) 10/25/2011

FEE TRANSMITTAL

*Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 2001.*

*Small Entity payments must be supported by a small entity statement,
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.*

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$848.00)

Complete if Known

Application Number	To be assigned
Filing Date	Herewith
First Named Inventor	Martyn Frank Burslem
Examiner Name	To be assigned
Group/Art Unit	To be assigned
Attorney Docket No.	PCS10895ADAM

METHOD OF PAYMENT (check one)

1. ☒ The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number Pfizer Inc.

Deposit Account Name 16-1445

☒ Charge Any Additional 37 Fee Required Under C.F.R. §§ 1.1.6 and 1.17 ☐ Charge the Issue Fee Set in 37 C.F.R. § 1.1.8 at the Mailing of the Notice of Allowance.

2. ☐ Payment Enclosed:
☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	740.00
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) (\$) 740.00

2. EXTRA CLAIM FEES

	Total Claims	Extra Claims	Fee from below	Fee Paid
Total Claims	20	-20**=	0 x 84.00	= 0.00
Independent Claims	9	- 3**=	6 x 18.00	= 108.00
Multiple Dependent			280.00	= 0.00

*** or number previously paid, if greater; For Reissues, see below*

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 108.00


FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee (specify) _____					
Other Fee (specify) _____					

*Reduced by Basic Filing Fee Paid


SUBTOTAL (3) (\$)

SUBMITTED BY				Complete (if Applicable)	
Type or Printed Name	Deborah A. Martin			Reg. Number	44,222
Signature				Deposit Account User ID	16-1445
Date	11-1-01				

EXPRESS MAIL NO. EL911724999 us

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to: Box SEQUENCE, Director - U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 1st day of November, 2001.

By


(Signature of person mailing)
Janice M. Denison

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **M. Frank Burslem, et al.** :

APPLICATION NO.: **To be assigned** : Examiner: **To be assigned**
FILING DATE: **Herewith** : Group Art Unit: **To be assigned**
TITLE: **Modulation of PDE11A Activity** :

Director - U.S. Patent and Trademark Office
Washington, D.C. 20231


STATEMENT REGARDING SUBMISSION
OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,

Date:

11-1-01


Deborah A. Martin
Attorney for Applicant(s)
Reg. No. 44,222

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-1821

EXPRESS MAIL NO. **EL9117249945**